Molecular determinants of chemotherapy resistance in ovarian cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular determinants of chemotherapy resistance in ovarian cancer
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 16, Issue 16, Pages 1763-1767
Publisher
Future Medicine Ltd
Online
2015-11-11
DOI
10.2217/pgs.15.130
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Summary of the 2015 American Association for Cancer Research (AACR) Annual Meeting
- (2015) Jeremy Chien et al. GYNECOLOGIC ONCOLOGY
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Mouse hospital and co-clinical trial project—from bench to bedside
- (2015) John G. Clohessy et al. Nature Reviews Clinical Oncology
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
- (2015) Nicholas McGranahan et al. Science Translational Medicine
- The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
- (2014) F. Fang et al. CLINICAL CANCER RESEARCH
- Tumour heterogeneity and the evolution of polyclonal drug resistance
- (2014) Rebecca A. Burrell et al. Molecular Oncology
- Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer
- (2013) W. Dai et al. CLINICAL CANCER RESEARCH
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
- (2013) Cory M. Johannessen et al. NATURE
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers
- (2013) Christopher J Lord et al. NATURE MEDICINE
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
- (2013) Jeremy Chien et al. Frontiers in Oncology
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
- (2012) A. K. Mitra et al. Cancer Discovery
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
- (2010) M Gerlinger et al. BRITISH JOURNAL OF CANCER
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Expression of the Major Fas Family and Bcl-2 Family of Proteins in Epithelial Ovarian Cancer (EOC) and Their Correlation to Chemotherapeutic Response and Outcome
- (2010) Parvesh Chaudhry et al. ONCOLOGY RESEARCH
- Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer
- (2009) Meng Li et al. BMC Medical Genomics
- Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas
- (2009) D. Etemadmoghadam et al. CLINICAL CANCER RESEARCH
- TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens
- (2008) Izabela Ziółkowska-Seta et al. GYNECOLOGIC ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started